NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the completion of the sale, the insider directly owned 69,302 shares of the company’s stock, valued at $1,864,916.82. The trade was a 64.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
NewAmsterdam Pharma Price Performance
Shares of NASDAQ:NAMS opened at $26.79 on Friday. The business’s 50-day moving average is $30.41 and its 200 day moving average is $31.98. NewAmsterdam Pharma Company N.V. has a 1 year low of $23.05 and a 1 year high of $42.21. The firm has a market capitalization of $3.20 billion, a P/E ratio of -12.40 and a beta of 0.10.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
Institutional investors and hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC boosted its position in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares during the last quarter. Wells Fargo & Company MN raised its position in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV acquired a new stake in NewAmsterdam Pharma during the 1st quarter valued at approximately $37,000. Navalign LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $46,000. Finally, AdvisorNet Financial Inc acquired a new stake in NewAmsterdam Pharma during the 1st quarter valued at approximately $82,000. Institutional investors and hedge funds own 89.89% of the company’s stock.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
